


MEDICAL INSIGHTS

HybridAPC for ablation of Barrett's esophagus after resection of neoplastic lesions

Randomized trial comparing HybridAPC to radiofrequency ablation



Background

On UEG week virtual 2020, data from a prospective, single-center, randomized trial was presented by Dr. Mate Knabe, University Hospital Frankfurt on October 11th in the Advanced endoscopic therapy session for the upper GI (Presentation OP023). The title of this publication was HYBRID ARGON-PLASMA-COAGULATION VERSUS RADIOFREQUENCY ABLATION IN BARRETT'S ESOPHAGUS AFTER ENDOSCOPIC RESECTION OF NEOPLASTIC LESIONS. A RANDOMIZED TRIAL AT A TERTIARY CENTER.

Barrett's esophagus describes an intestinal metaplasia of the esophageal squamous epithelium. A neoplasia in Barrett's esophagus is resected endoscopically, if possible, followed by ablation of the remaining metaplastic Barrett's mucosa in another session. Manner et al. showed in the APE trial that without an ablation, around one third of these patients will present with a recurrent neoplastic lesion¹.

Challenges and goals

After resection of neoplastic tissue with EMR or ESD, the remaining Barrett's mucosa is ablated irrespective of the presence of dysplasia. Complications such as esophageal strictures, pain or incomplete eradication can occur.

Different technologies exist for ablation of Barrett's mucosa, including HybridAPC. To date, only limited data comparing the technologies are available. The BRIDE trial in 2019 compared conventional APC to radiofrequency ablation and is of limited value for comparison with the present results².

Method

Knabe et al. conducted a prospective, randomized trial including 103 consecutive patients with Barrett's esophagus who underwent ablation two months after EMR of a neoplastic lesion. All patients with at least 1 cm longitudinal extent of Barrett's mucosa were randomly assigned to either radiofrequency ablation or ablation with HybridAPC. For radiofrequency ablation, a simplified protocol was used (see image). Patients in the HybridAPC group were treated with a single ablation per session with a power limitation of 60W. In contrast to previous trials, no scraping with the endoscope cap and second ablation were performed.

A follow-up endoscopic examination was performed at 3, 6, 12 and 24 months. The ablation was deemed successful if on a follow-up examination 6 months after ablation, a normal neo Z-line was visible and eradication was proven in biopsies. Furthermore, stricture rates, post-interventional pain and pain duration were recorded.

References

1. Manner H, Rabenstein T, Pech O, Braun K, May A, Pohl J, Behrens A, Vieth M, Ell C. Ablation of residual Barrett's epithelium after endoscopic resection: a randomized long-term follow-up study of argon plasma coagulation vs. surveillance (APE study). *Endoscopy*. 2014 Jan;46(1):6-12. doi: 10.1055/s-0033-1358813. Epub 2013 Dec 18. PMID: 24353120.
2. Peerally MF, Bhandari P, Ragunath K, Barr H, Stokes C, Haidry R, Lovat L, Smart H, Harrison R, Smith K, Morris T, de Caestecker JS. Radiofrequency ablation compared with argon plasma coagulation after endoscopic resection of high-grade dysplasia or stage T1 adenocarcinoma in Barrett's esophagus: a randomized pilot study (BRIDE). *Gastrointest Endosc*. 2019 Apr;89(4):680-689. doi: 10.1016/j.gie.2018.07.031. Epub 2018 Aug 1. PMID: 30076843.

Results and key findings

The eradication rate proved non-significant difference on a high level for both technologies. A trend towards less post-interventional pain and a shorter duration with HybridAPC was shown. The stricture rate of 2% at the 6-month follow-up examination was significantly lower for patients treated with HybridAPC compared to the RFA group.


	HybridAPC group (n=55)	RFA group (n=48)
Post-interventional pain level (as per NAS)	2.1/10	4.1/10
Pain duration in days	3.3	5.7
Complete eradication at 6-month follow-up in %	91	87
Stricture rate in %	2	13

Implications and recommendations

Due to the substantial difference in the stricture rate, Knabe and colleagues decided to stop enrolling after 103 patients for this study. The preliminary results to date have not yet been published.

Products

The present trial was conducted using the HybridAPC probes. A pulsed mode (VIO® 300D & APC 2, PULSED APC®, Effect 2) with a power limitation of 60W was used. ERBEJET® 2 was used with an effect setting of 40–50.



Important information

We have prepared this document with care. Nonetheless, we cannot completely rule out errors in this document.

The information, recommendations and other data ("Information") contained in this document reflect our state of knowledge and the state of science and technology at the time of preparing the document. The information is of a general nature, non-binding and serves solely for general information purposes and does not represent instructions for use or notes on application.

The information and recommendations contained in this document do not constitute any legal obligations on Erbe Elektromedizin GmbH or their associated companies ("Erbe") or any other claims against Erbe. The information does not represent a guarantee or other quality statement; these require an express contractual arrangement with Erbe in individual cases.

Erbe shall not be liable for any type of damage resulting from following information given in this document, regardless of the legal reason for liability.

Every user of an Erbe product is responsible for checking the respective Erbe product for its properties as well as the suitability for the intended type of application or intended purpose in advance. The suitable type of application of the respective Erbe product is given by the user manual and the notes on use for the corresponding Erbe product. The user is obliged to check whether the existing user manual and the notes on use correspond with the status for the specific Erbe product. The devices may only be used according to the user manual and the notes on use.

The information on setting values, application sites, duration of application and the use of the respective Erbe product is based on the clinical experience of physicians independent from Erbe. They represent guidelines which need to be checked by the user for their suitability for the actual planned application. Depending on the circumstances of an actual application case, it may be necessary to deviate from the information provided. The user is responsible for checking this in each case when using an Erbe product. We wish to point out that science and technology is constantly subject to new developments arising from research and clinical experience. For this reason, it may be necessary for the user to deviate from the information provided in this document.

This document contains information about Erbe products which may possibly not be approved in a specific country. The user of the respective Erbe product is obliged to inform him/herself as to whether the Erbe product he/she is using is legally approved in his/her country and/or if legal requirements or restrictions for use possibly exist and to what extent.

This document is not intended for users in the USA.

Erbe Elektromedizin GmbH
Waldhoernlestrasse 17
72072 Tuebingen
Germany

Phone +49 7071 755-0
info@erbe-med.com
erbe-med.com
medical-videos.com